Am J Health Syst Pharm. 2007;64(11):1174-1186. In the British study, 495 patients received droperidol 2.5-50 mg p.o. for the treatment of psychiatric illness and were compared with 101 healthy ...

Purpose: Data collected from the Food and Drug Administration (FDA) under the Freedom of Information Act are presented to help clinicians understand the data prompting the black-box warning for ...

The FDA has accepted the NDA for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.

Cyclobenzaprine is a generic prescription oral tablet used to treat muscle spasms. It does not come in any brand-name versions. Cyclobenzaprine can cause mild to serious side effects, including ...

TNX-102 SL is a non-opioid, centrally-acting analgesic administered at bedtime for the treatment of fibromyalgia. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA ...

for TNX-102 SL (cyclobenzaprine HCl sublingual tablets), a 5.6 mg, non-opioid, centrally-acting analgesic, for the management of fibromyalgia. The FDA is expected to assign the NDA a Prescription ...

for TNX-102 SL (cyclobenzaprine HCl sublingual tablets), a 5.6 mg, non-opioid, centrally-acting analgesic, for the management of fibromyalgia. The FDA is expected to assign the NDA a Prescription Drug ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...